Literature DB >> 20113370

PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance.

Joanne E Konkel1, Friederike Frommer, Melanie D Leech, Hideo Yagita, Ari Waisman, Stephen M Anderton.   

Abstract

The ultimate outcome of T-cell recognition of peptide-major histocompatibility complex (MHC) complexes is determined by the molecular context in which antigen presentation is provided. The paradigm is that, after exposure to peptides presented by steady-state dendritic cells (DCs), inhibitory signals dominate, leading to the deletion and/or functional inactivation of antigen-reactive T cells. This has been utilized in a variety of models providing peptide antigen in soluble form in the absence of adjuvant. A co-inhibitory molecule of considerable current interest is PD-1. Here we show that there is the opportunity for the PD-1/PD-L1 interaction to function in inhibiting the T-cell response during tolerance induction. Using traceable CD4(+) T-cell receptor (TCR) transgenic cells, together with a blocking antibody to disrupt PD-1 signalling, we explored the roles of PD-1 in the induction of tolerance versus a productive immune response. Intact PD-1 signalling played a role in limiting the extent of CD4(+) T-cell accumulation in response to an immunogenic stimulus. However, PD-1 signalling was not required for either the induction, or the maintenance, of peptide-induced tolerance; a conclusion underlined by successful tolerance induction in TCR transgenic cells genetically deficient for PD-1. These observations contrast with the reported requirement for PD-1 signals in CD8(+) T-cell tolerance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20113370      PMCID: PMC2855797          DOI: 10.1111/j.1365-2567.2009.03216.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  38 in total

Review 1.  Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance.

Authors:  Ralph Marvin Steinman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

2.  Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses.

Authors:  Spencer C Liang; Yvette E Latchman; Janet E Buhlmann; Michal F Tomczak; Bruce H Horwitz; Gordon J Freeman; Arlene H Sharpe
Journal:  Eur J Immunol       Date:  2003-10       Impact factor: 5.532

3.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.

Authors:  Kelly-Ann Sheppard; Lori J Fitz; Julie M Lee; Christina Benander; Judith A George; Joe Wooters; Yongchang Qiu; Jason M Jussif; Laura L Carter; Clive R Wood; Divya Chaudhary
Journal:  FEBS Lett       Date:  2004-09-10       Impact factor: 4.124

4.  Expression of programmed death 1 ligands by murine T cells and APC.

Authors:  Tomohide Yamazaki; Hisaya Akiba; Hideyuki Iwai; Hironori Matsuda; Mami Aoki; Yuka Tanno; Tahiro Shin; Haruo Tsuchiya; Drew M Pardoll; Ko Okumura; Miyuki Azuma; Hideo Yagita
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

5.  PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.

Authors:  LauraL Carter; Lynette A Fouser; Jason Jussif; Lori Fitz; Bija Deng; Clive R Wood; Mary Collins; Tasuku Honjo; Gordon J Freeman; Beatriz M Carreno
Journal:  Eur J Immunol       Date:  2002-03       Impact factor: 5.532

6.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

7.  Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Authors:  Brian T Fife; Kristen E Pauken; Todd N Eagar; Takashi Obu; Jenny Wu; Qizhi Tang; Miyuki Azuma; Matthew F Krummel; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2009-09-27       Impact factor: 25.606

8.  Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis.

Authors:  Estelle Bettelli; Maria Pagany; Howard L Weiner; Christopher Linington; Raymond A Sobel; Vijay K Kuchroo
Journal:  J Exp Med       Date:  2003-05-05       Impact factor: 14.307

9.  Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis.

Authors:  Alan D Salama; Tanuja Chitnis; Jaime Imitola; Mohammed Javeed I Ansari; Hisaya Akiba; Fumihiko Tushima; Miyuki Azuma; Hideo Yagita; Mohamed H Sayegh; Samia J Khoury
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

10.  The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.

Authors:  Mohammed Javeed I Ansari; Alan D Salama; Tanuja Chitnis; R Neal Smith; Hideo Yagita; Hisaya Akiba; Tomohide Yamazaki; Miyuki Azuma; Hideyuki Iwai; Samia J Khoury; Hugh Auchincloss; Mohamed H Sayegh
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

View more
  15 in total

1.  Role of TLR2-dependent IL-10 production in the inhibition of the initial IFN-γ T cell response to Porphyromonas gingivalis.

Authors:  Dalia E Gaddis; Craig L Maynard; Casey T Weaver; Suzanne M Michalek; Jannet Katz
Journal:  J Leukoc Biol       Date:  2012-10-17       Impact factor: 4.962

2.  Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Authors:  Blanca Homet Moreno; Jesse M Zaretsky; Angel Garcia-Diaz; Jennifer Tsoi; Giulia Parisi; Lidia Robert; Katrina Meeth; Abibatou Ndoye; Marcus Bosenberg; Ashani T Weeraratna; Thomas G Graeber; Begoña Comin-Anduix; Siwen Hu-Lieskovan; Antoni Ribas
Journal:  Cancer Immunol Res       Date:  2016-09-02       Impact factor: 11.151

Review 3.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

4.  Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.

Authors:  Annika Fendler; Lewis Au; Scott T C Shepherd; Fiona Byrne; Maddalena Cerrone; Laura Amanda Boos; Karolina Rzeniewicz; William Gordon; Benjamin Shum; Camille L Gerard; Barry Ward; Wenyi Xie; Andreas M Schmitt; Nalinie Joharatnam-Hogan; Georgina H Cornish; Martin Pule; Leila Mekkaoui; Kevin W Ng; Eleanor Carlyle; Kim Edmonds; Lyra Del Rosario; Sarah Sarker; Karla Lingard; Mary Mangwende; Lucy Holt; Hamid Ahmod; Richard Stone; Camila Gomes; Helen R Flynn; Ana Agua-Doce; Philip Hobson; Simon Caidan; Michael Howell; Mary Wu; Robert Goldstone; Margaret Crawford; Laura Cubitt; Harshil Patel; Mike Gavrielides; Emma Nye; Ambrosius P Snijders; James I MacRae; Jerome Nicod; Firza Gronthoud; Robyn L Shea; Christina Messiou; David Cunningham; Ian Chau; Naureen Starling; Nicholas Turner; Liam Welsh; Nicholas van As; Robin L Jones; Joanne Droney; Susana Banerjee; Kate C Tatham; Shaman Jhanji; Mary O'Brien; Olivia Curtis; Kevin Harrington; Shreerang Bhide; Jessica Bazin; Anna Robinson; Clemency Stephenson; Tim Slattery; Yasir Khan; Zayd Tippu; Isla Leslie; Spyridon Gennatas; Alicia Okines; Alison Reid; Kate Young; Andrew J S Furness; Lisa Pickering; Sonia Gandhi; Steve Gamblin; Charles Swanton; Emma Nicholson; Sacheen Kumar; Nadia Yousaf; Katalin A Wilkinson; Anthony Swerdlow; Ruth Harvey; George Kassiotis; James Larkin; Robert J Wilkinson; Samra Turajlic
Journal:  Nat Cancer       Date:  2021-10-27

Review 5.  Senescent cells: an emerging target for diseases of ageing.

Authors:  Bennett G Childs; Martina Gluscevic; Darren J Baker; Remi-Martin Laberge; Dan Marquess; Jamie Dananberg; Jan M van Deursen
Journal:  Nat Rev Drug Discov       Date:  2017-07-21       Impact factor: 84.694

6.  Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response.

Authors:  Yuxiang Rui; Tasuku Honjo; Shunsuke Chikuma
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

7.  Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease.

Authors:  Maida Wong; Antonio La Cava; Bevra H Hahn
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

8.  Combination peptide immunotherapy based on T-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation.

Authors:  Karen J Mackenzie; Paul M Fitch; Melanie D Leech; Anne Ilchmann; Claire Wilson; Amanda J McFarlane; Sarah E M Howie; Stephen M Anderton; Jürgen Schwarze
Journal:  Immunology       Date:  2013-03       Impact factor: 7.397

9.  Monitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.

Authors:  J Lori Blanchfield; Shayla K Shorter; Brian D Evavold
Journal:  Front Immunol       Date:  2013-07-03       Impact factor: 7.561

10.  Effector and central memory T helper 2 cells respond differently to peptide immunotherapy.

Authors:  Karen J Mackenzie; Dominika J Nowakowska; Melanie D Leech; Amanda J McFarlane; Claire Wilson; Paul M Fitch; Richard A O'Connor; Sarah E M Howie; Jürgen Schwarze; Stephen M Anderton
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.